Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAND567 versus placebo in anterior STEMI patients undergoing PCI
ISRCTN18402242Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Nov 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of rugocrixan in myocardial infarction (MI), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Occurrence of adverse events. Started Nov 2021; status: completed.
02
Drugs
rugocrixan
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ISRCTN18402242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18402242.